创模生物科技(北京)有限公司

CN / En

NEWS

InnoModels Biotechnology: What are the features of the CDX platform?

  • Categories:Company news
  • Author:InnoModels
  • Origin:InnoModels
  • Time of issue:2024-06-06 15:04
  • Views:

(Summary description)With the rapid development in the field of biomedicine, cancer research and treatment has entered a brand new era. In this era, an efficient and precise experimental platform has become the key for scientists to overcome cancer. The InnoModels Biotechnology CDX platform was born out of necessity, and with its unique features and advantages, it is gradually becoming a new favorite in the field of cancer research and treatment.

InnoModels Biotechnology: What are the features of the CDX platform?

(Summary description)With the rapid development in the field of biomedicine, cancer research and treatment has entered a brand new era. In this era, an efficient and precise experimental platform has become the key for scientists to overcome cancer. The InnoModels Biotechnology CDX platform was born out of necessity, and with its unique features and advantages, it is gradually becoming a new favorite in the field of cancer research and treatment.

  • Categories:Company news
  • Author:InnoModels
  • Origin:InnoModels
  • Time of issue:2024-06-06 15:04
  • Views:
Information

With the rapid development in the field of biomedicine, cancer research and treatment has entered a brand new era. In this era, an efficient and precise experimental platform has become the key for scientists to overcome cancer. The InnoModels Biotechnology CDX platform was born out of necessity, and with its unique features and advantages, it is gradually becoming a new favorite in the field of cancer research and treatment.
First of all, InnoModels Biotechnology CDX platform has a huge tumor cell line library. This platform brings together more than 400 different tumor cell lines, covering a wide range of cancer types and subtypes. This diverse library of tumor cell lines provides researchers with a wealth of choices, enabling them to select the most appropriate cell line for a specific research area. This flexibility ensures the depth and breadth of research and provides a solid foundation for precision cancer treatment.
Secondly, the InnoModels CDX platform focuses on preserving the original heterogeneity. By maintaining the heterogeneity of the original cancer tissue, the platform enables researchers to gain a more comprehensive understanding of the complex characteristics of tumors. This heterogeneity is critical in cancer research because it helps reveal the mechanisms of tumorigenesis, progression and metastasis. Through the CDX platform, scientists can delve into the biology of tumor cells, providing a more accurate data base for precision medicine.
Furthermore, the InnoModels CDX platform is highly portable, and the high portability of CDX graft tumors in animals makes it an ideal tool for drug discovery and development. Through the CDX platform, researchers can simulate the growth and spreading process of human tumors in animals, so as to evaluate the therapeutic effects of different drugs on tumors. This feature provides a fast and efficient experimental tool for drug development and accelerates the process of new drug development.

 


In addition, InnoModels' CDX platform is widely used in the research of various cancer types. Whether it is breast cancer, lung cancer or colorectal cancer, etc., the platform can provide strong support for researchers. This wide range of applications makes the CDX platform a bridge for interdisciplinary cancer research and promotes synergistic collaboration between different fields.
It is worth noting that the InnoModels Biotechnology CDX platform also excels in data integrity and regulatory compliance. The platform maintains thorough and traceable experimental records, making research data more reliable and credible. This provides researchers with a strong guarantee that their studies will comply with industry standards and regulatory requirements.
In summary, with its large tumor cell line library, ability to preserve original heterogeneity, high portability, and wide range of applications, the InnoModels Biotechnology CDX platform shows strong potential in the field of cancer research and treatment. The platform provides scientists with an efficient and precise experimental platform, offering new hope for overcoming the worldwide challenge of cancer. In the future, with the continuous progress and innovation of the technology, the InnoModels Biotechnology CDX platform will continue to fulfill its unique advantages and bring more breakthroughs and achievements in the field of cancer research and treatment.

Keyword:

In the vast field of oncology and tumor immunopharmacodynamics research, InnoModels Biotechnology (Beijing) Ltd. has become a leader in the industry with its outstanding innovation ability and profound scientific research background. This company, co-founded by scientists from Novo Nordisk China R&D Center, Sino-US Crown and Shanghai Jiao Tong University Institute of Immunology, has been committed to building a stable domestic platform of humanized mouse models of the immune system (HIS) and human tumor xenografts (PDX) since its establishment in 2020, to provide new drug discovery and development companies, translational medicine researchers, and tumor patients with new-generation laboratory animal models for new drug discovery companies, translational medicine researchers, and tumor patients
In recent years, many breakthroughs have been made in the field of biomedical research, among which iHuPBMC-T technology is undoubtedly a shining star. As an innovative platform built by InnoModels Biotechnology (Beijing) Co., Ltd, iHuPBMC-T, with its unique technological advantages, shows great potential in optimizing the reconstruction of human peripheral blood single nucleated cell (PBMC) model and immuno-oncology research.
Recently, InnoModels Biotechnology (Beijing) Co., Ltd. has made a major breakthrough in the field of pharmaceutical technology, and successfully obtained a patent entitled “Method and application for the detection of immune system rebuilding ability of PBMC”. This patent not only adds a new footnote to the R&D strength of InnoModels Biotechnology in the field of biomedicine, but also provides a strong technical support for the promotion of drug research and development and the establishment of humanized experimental animal models
With the rapid development of biotechnology, the in-depth study of the immune system has become the key to new drug discovery, disease diagnosis and treatment. InnoModels Bio-technology (Beijing) Co., Ltd. provides strong support for researchers with its profound scientific background and advanced technology platform. Among them, the ELISpot platform of InnoModels Biotechnology has made a name for itself in the field of immunology research with its high sensitivity and multi-functionality
InnoModels' ADCC platform plays a pivotal role in advancing cancer treatment, and its unique technological advantages and innovative concepts have brought about a far-reaching impact on the field of tumor immunotherapy. The following is a detailed introduction of how the platform promotes the advancement of cancer treatment
In the field of tumor immunotherapy, complement-dependent cytotoxicity (CDC), as an important therapeutic mechanism, is gradually showing its great potential and value. In order to explore this mechanism more deeply, with its profound accumulation in the field of oncology and tumor immunopharmacodynamics CRO services, InnoModels Biotechnology (Beijing) Co., Ltd. has launched the CDC in vitro immune-tumor cell co-culture killing experimental platform, which provides researchers with a powerful and precise tool to help innovate cancer treatment
Previous page
1
2
43
  • Tel 15010000264
  • E-mail limy@imodels.tech
  • Tel 13810723384
  • Top

InnoModels Biotechnology (Beijing) Co., Ltd.

TEL:15010000264        13810723384

Address:Building 14, Life Valley, Shuangying West Road, Changping District, Beijing

Chuangmo Biotechnology (Beijing) Co., Ltd. Beijing ICP 222*** 98-1 Website Construction: China Enterprise Power Beijing Second Branch Company

北京中因科技有限公司

创模生物科技(北京)有限公司